A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

被引：4

作者：

Nazha, Aziz ^{[1
]}

Komrokji, Rami S. ^{[2
]}

Garcia-Manero, Guillermo ^{[3
]}

Barnard, John ^{[4
]}

Zell, Katrina ^{[4
]}

Zimmerman, Cassie ^{[4
]}

Al Ali, Najla H. ^{[5
]}

Roboz, Gail J. ^{[6
]}

Steensma, David P. ^{[7
]}

DeZern, Amy E. ^{[8
]}

Padron, Eric ^{[5
]}

Jabbour, Elias J. ^{[3
]}

Greenberg, Molly Dara ^{[9
]}

List, Alan F. ^{[10
]}

Kantarjian, Hagop M. ^{[3
]}

Maciejewski, Jaroslaw P. ^{[11
]}

Sekeres, Mikkael A. ^{[4
]}

机构：

[1] Cleveland Clin, Dept Hematol & Oncol, Leukemia Program, Taussig Canc Inst, Cleveland, OH 44106 USA

[2] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[4] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA

[5] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol Dept, Tampa, FL 33612 USA

[6] Weill Cornell Med Coll, Joan & Sanford I Weill Dept Med, New York, NY USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[9] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA

[10] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL 33612 USA

[11] Cleveland Clin, Taussig Canc Inst, Taussig Canc Ctr, Expt Hematol & Hematopoiesis Sect, Cleveland, OH 44106 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.2861.2861

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure
Nazha, Aziz
Komrokji, Rami S.
Garcia-Manero, Guillermo
Barnard, John
Zimmerman, Cassie
Najla, Al Ali
Roboz, Gail J.
Steensma, David P.
DeZern, Amy E.
Jabbour, Elias
Lee, Sangmin
Greenberg, Molly D.
List, Alan F.
Kantarjian, Hagop M.
Maciejewski, Jaroslaw P.
Sekeres, Mikkael A.
[J]. BLOOD, 2014, 124 (21)
[2] Multicenter Validation of a Personalized Model to Predict Hypomethylating Agent Response in Myelodysplastic Syndromes (MDS)
Radakovich, Nathan
Sallman, David A.
Buckstein, Rena J.
Brunner, Andrew M.
Mukherjee, Sudipto
Komrokji, Rami
Al Ali, Najla
Shreve, Jacob
Rouphail, Yazan
Kerr, Cassandra M.
Guan, Yihong
Kuzmanovic, Teodora
Hasipek, Metis
Jha, Babal K.
Maciejewski, Jaroslaw P.
Sekeres, Mikkael A.
Nazha, Aziz
[J]. BLOOD, 2020, 136
[3] The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
Nazha, Aziz
Komrokji, Rami S.
Garcia-Manero, Guillermo
Barnard, John
Roboz, Gail J.
Steensma, David P.
DeZern, Amy E.
Zell, Katrina
Zimmerman, Cassie
Al Ali, Najla
Jabbour, Elias
Greenberg, Molly D.
Kantarjian, Hagop M.
Maciejewski, Jaroslaw P.
List, Alan F.
Sekeres, Mikkael A.
[J]. HAEMATOLOGICA, 2016, 101 (06) : E224 - E227
[4] Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)
Nazha, Aziz
Sekeres, Mikkael A.
Bejar, Rafael
Komrokji, Rami S.
Barnard, John
Al-Issa, Karam
Przychodzen, Bartlomiej P.
Hirsch, Cassandra M.
Steensma, David P.
DeZern, Amy E.
Roboz, Gail J.
Garcia-Manero, Guillermo
Ebert, Benjamin L.
Maciejewski, Jaroslaw P.
[J]. BLOOD, 2017, 130
[5] Budget Impact Model for Hypomethylating Agent Use for the Treatment of Myelodysplastic Syndromes (MDS)
Feinberg, Bruce
Scott, Jeffrey
Weidner, Susan
Fortner, Barry
[J]. BLOOD, 2008, 112 (11) : 835 - 836
[6] Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes
Chien, Kelly S.
Urrutia, Samuel
Li, Ziyi
Kanagal-Shamanna, Rashmi
Abdelhakeem, Ahmed
Abuasab, Tareq
Almanza, Emmanuel
Gener-Ricos, Georgina
Bataller, Alex
Bazinet, Alexandre
Montalban-Bravo, Guillermo
Short, Nicholas J.
Jabbour, Elias
Kadia, Tapan M.
Ravandi, Farhad
Borthakur, Gautam
Hammond, Danielle E.
Swaminathan, Mahesh
Sasaki, Koji
Dong, Xiao Qin
Pierce, Sherry
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
[J]. BLOOD, 2023, 142
[7] Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes
Chien, Kelly
Kim, Kunhwa
Li, Ziyi
Shamanna, Rashmi Kanagal
Ong, Faustine
Bravo, Guillermo Montalban
Kadia, Tapan
Jabbour, Elias
Pemmaraju, Naveen
Hammond, Danielle
Short, Nicholas
Ravandi, Farhad
Alvarado, Yesid
Pierce, Sherry
Dong, Xiao Qin
Kantarjian, Hagop
Garcia-Manero, Guillermo
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S311 - S311
[8] Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
Carraway, Hetty E.
[J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 470 - 477
[9] A Phase II Study of CPX-351 As a Novel Therapeutic Approach for Patients with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent Failure
Nazha, Aziz
Mukherjee, Sudipto
Advani, Anjali S.
Waldron, Madeline
Siebenaller, Caitlin
Thomas, Jenna
Parsons, Eric
Carraway, Hetty E.
Gerds, Aaron T.
Patel, Bhumika J.
Sekeres, Mikkael A.
[J]. BLOOD, 2020, 136
[10] A PHASE I TRIAL OF IPILIMUMAB (IPI) IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS) AFTER HYPOMETHYLATING AGENT (HMAS) FAILURE
Zeidan, A.
Knaus, H.
Robinson, T.
Zeidner, J.
Blackford, A.
Duffield, A.
Rizzieri, D.
Frattini, M.
Levy, M. Y.
Schroeder, M.
Ferguson, A.
Sheldon, K.
Dezern, A.
Gojo, I.
Gore, S.
Streicher, H.
Luznik, L.
Smith, B. D.
[J]. LEUKEMIA RESEARCH, 2017, 55 : S43 - S43

← 1 2 3 4 5 →